Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Juvenile Myositis: Insights on Classification, Pathogenesis and Therapies over the Past 50 Years.

Arthritis care & research·2026
Same author

A test of a conceptual model of uncertainty, benefit and burden in children and young people with juvenile dermatomyositis.

Rheumatology advances in practice·2026
Same author

Mortality rates in children, young people, and young adults with JIA: an observational study using the Clinical Practice Research Datalink (CPRD).

EULAR rheumatology open·2026
Same author

Opinions on contributing data to research studies: survey results from adults living with juvenile idiopathic arthritis (JIA).

Rheumatology (Oxford, England)·2026
Same author

Referral, treatment patterns and change in quality of life in the first twelve months in children and young people with Juvenile Idiopathic Arthritis: an analysis of the association with ethnicity and socioeconomic position using data from a cohort study.

Rheumatology (Oxford, England)·2026
Same author

Functional and dysfunctional T regulatory cell states in human tissues in RA and other autoimmune arthritic diseases.

Nature immunology·2026

Related Experiment Videos

Update in juvenile myositis.

Kiran Nistala1, Lucy R Wedderburn

  • 1aCentre for Rheumatology, University College London bRheumatology Unit, UCL Institute for Child Health, London cArthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH and GOSH, UK.

Current Opinion in Rheumatology
|September 25, 2013
PubMed
Summary

Recent studies reveal adaptive immune system abnormalities in childhood idiopathic inflammatory myopathies (IIMs), particularly juvenile dermatomyositis (JDM). New remission criteria and insights into autoantibodies offer hope for improved JDM treatment.

Related Experiment Videos

Area of Science:

  • Pediatric Rheumatology
  • Translational Science
  • Immunology

Background:

  • Childhood idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases requiring ongoing research.
  • Understanding the underlying immune mechanisms is crucial for effective treatment strategies.

Purpose of the Study:

  • To review recent advancements in translational science and clinical research for childhood IIMs.
  • To highlight progress in understanding the etiology, treatment, and prognosis of juvenile idiopathic inflammatory myopathies.

Main Methods:

  • Review of recent international genome-wide association studies.
  • Analysis of findings from clinical trials, including B-cell depletion therapy.
  • Incorporation of newly established international definitions for disease remission.

Main Results:

  • Evidence suggests abnormalities in the adaptive immune system contribute to childhood IIMs.
  • T-follicular helper cells and specific autoantibodies (e.g., anti-NXP-2) are implicated in juvenile dermatomyositis (JDM).
  • A clinical trial of rituximab showed potential benefits in JDM patients despite not meeting primary endpoints for all IIMs.

Conclusions:

  • Collaborative research efforts are overcoming challenges in studying rare diseases like JDM.
  • Significant progress has been made in understanding the causes, treatments, and outcomes of childhood IIMs.
  • A new international definition of JDM remission will standardize assessment in future trials.